Perspective Therapeutics, Inc.
HealthcareAMEX:CATX · New York Stock Exchange American
-$0.02 today
Vol 0.94M · Avg 1.44M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$618.0K of revenue converted into -$111.1M of net income for the selected period. Gross margin is -451.3% and net margin is -13573.3%, showing how much revenue survives after costs and taxes. EPS is $-26.44, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $884.0K | $0 -100.0% | $1.4M -79.8% | $7.1M -34.2% | $10.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 -100.0% | $5.5M -11.5% | $6.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$2.4M | $0 -100.0% | $1.4M -12.2% | $1.6M -64.6% | $4.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | -267.8% | — | 100.0% +77.0pp | 23.0% -19.8pp | 42.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $84.2M +102.3% | $41.6M +95.4% | $21.3M +719.0% | $2.6M +0.8% | $2.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $30.2M +13.6% | $26.6M +26.3% | $21.1M +48.2% | $14.2M +50.8% | $9.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $113.6M +23.0% | $92.3M +117.9% | $42.4M +143.2% | $17.4M +45.1% | $12.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.3M +41.0% | $2.3M +135.1% | $981.0K +185.2% | $344.0K +38.7% | $248.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$100.8M -1063.8% | $10.5M +126.2% | -$40.0M -169.3% | -$14.8M -100.8% | -$7.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -11402.8% | — | -2786.6% -2577.7pp | -208.9% -140.4pp | -68.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$113.6M -1185.8% | $10.5M +125.5% | -$40.9M -169.7% | -$15.2M -105.4% | -$7.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -12846.6% | — | -2855.0% -2641.3pp | -213.7% -145.2pp | -68.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $8.1M -22.8% | $10.5M +1025.8% | $934.0K -16.8% | $1.1M +842.9% | $119.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $376.0K +883.3% | -$48.0K -157.1% | $84.0K | $0 -100.0% | $119.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $9.1M +109.9% | -$91.8M -11098.2% | $835.0K +63.1% | $512.0K +330.3% | $119.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$104.4M -28.3% | -$81.4M -102.9% | -$40.1M -173.4% | -$14.7M -101.7% | -$7.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -11813.1% | — | -2796.8% -2590.3pp | -206.5% -139.1pp | -67.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$793.0K +62.2% | -$2.1M +20.9% | -$2.7M | $0 +100.0% | -$119.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$103.1M -30.1% | -$79.3M -70.5% | -$46.5M -217.0% | -$14.7M -105.1% | -$7.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -11665.3% | — | -3243.2% -3036.7pp | -206.5% -140.2pp | -66.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -13.8% | -$1 -44.7% | -$1 -214.8% | -$0 -107.7% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -13.8% | -$1 -44.7% | -$1 -214.8% | -$0 -107.7% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $73.8M +14.6% | $64.4M +17.3% | $54.9M +0.0% | $54.9M +0.0% | $54.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $73.8M +14.6% | $64.4M +17.3% | $54.9M +0.0% | $54.9M +0.0% | $54.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Electromed, Inc.
AMEX:ELMD
$307.52M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Solana Company
NASDAQ:HSDT
$89.92M
Nyxoah S.A.
NASDAQ:NYXH
$55.05M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CATX generate?
Perspective Therapeutics, Inc. (CATX) reported $884,000.00 of revenue in fiscal 2025.
Is CATX profitable?
Perspective Therapeutics, Inc. (CATX) reported -$103,121,000.00 of net income, with a net margin of -11665.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.